AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. Other stock markets 16:35:05 17/02/2026 GMT			5-day change	1st Jan Change
15,522.00 ^GBX	+2.39%		+9.59%	+12.56%

07:12am	Jane Buus Laursen Appointed CCDO at Camurus	FW
02-16	Oddo BHF raises TP for AstraZeneca shares

AstraZeneca plc Announces Executive Changes , Effective March 1, 2026

Published on 01/08/2026 at 08:20 am GMT

S&P Capital IQ

ASTRAZENECA PLC

+2.39%

AstraZeneca PLC appointed Joris Silon as Head of Investor Relations, effective March 1, 2026. Joris is moving from his role as the country president of AstraZeneca US where he led and delivered significant growth for the Company in its largest market. Joris brings extensive pharmaceutical experience, having joined the Company in 2000 and has held leadership positions in Asia, Europe and the US.

Andy Barnett, the outgoing Head of Investor Relations, is transitioning to a new role within AstraZeneca after leading the Investor Relations team for four years.

Latest news about AstraZeneca PLC

07:12am	Jane Buus Laursen Appointed CCDO at Camurus	FW
02-16	Oddo BHF raises TP for AstraZeneca shares
02-16	ASTRAZENECA : Deutsche Bank maintains a Sell rating	ZD
02-16	RBC cuts Schroders, LBBW says 'hold' Unilever	AN
02-16	Tellus Midas Rises 0.9 Percent in January – Positive Outlook for 2026 Stock Market	FW
02-16	Galderma Group AG Announces the Appointment of Luigi La Corte as Chief Financial Officer, Effective May 1, 2026	CI
02-13	Sector Update: Health Care Stocks Advance Late Afternoon	MT
02-13	Sector Update: Health Care Stocks Higher Friday Afternoon	MT
02-13	European Equities Mixed in Friday Trading; Spain's January CPI Declines	MT
02-13	AstraZeneca Announces Positive and clinically meaningful Results from the Phase III KALOS and Logos Trials for Breztri in Patients with Undundant Ast Astrazeneca's Breztri in Patients	CI
02-13	Shore Capital Downgrades AstraZeneca to Hold Rating	MT
02-13	Stocks edge lower ahead of US CPI data	AN
02-13	Stockholm Stock Exchange Declines on Friday After Intense Earnings Week	FW
02-13	ASTRAZENECA : Bernstein maintains a Buy rating	ZD
02-13	Bernstein, Barclays and Deutsche lower Relx	AN

Chart AstraZeneca PLC

Duration

Period

AZN: Dynamic Chart

Company Profile

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (94.2%). Net sales break down by treatment area between oncology (39.8%), cardiovascular, renal and metabolic diseases (24.4%), respiratory and autoimmune diseases (14.6%), and other (21.2%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (5.8%). Net sales are distributed geographically as follows: the United Kingdom (8.8%), Europe (21.6%), the United States (40.3%), Americas (5.9%) and Africa/Asia/Australia (23.4%).

Employees

94,300

Sector

Pharmaceuticals

Calendar

03-02 - Daiwa Tokyo Investment Conference

More about the company